VNDA — Vanda Pharmaceuticals Inc. Dilution Risk Tracker

Vanda Pharmaceuticals Inc. (VNDA) has a DilutionScore of 46/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

The most significant dilution vector for VNDA is its shelf registration capacity of $200.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. Cash runway is a key watch item: VNDA has approximately 15 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for VNDA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for VNDA alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.